Navigation Links
Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
Date:6/2/2008

Oxygent Development Update

Alliance has been transferring the manufacturing technology to enable its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane) to manufacture Oxygent in China. To date, Double-Crane has built out the manufacturing facility and has ordered the key equipment, such as tanks, process mixers, pumps, etc. It has also produced the Active Pharmaceutical Ingredient (API), perfluorooctylbromide, in pilot scale quantities. Following the manufacture of clinical supplies in China, Double-Crane plans to submit an IND to the SFDA, which is anticipated to be completed in 2008. Alliance has provided Double-Crane Phase 1 and Phase 2 with clinical trial protocols for translation and eventual submission.

About Alliance Pharmaceutical Corp.

Alliance is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent, which is based on its proprietary perfluorochemical technology. Oxygent is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein. Alliance refers you to cautionary information contained in documents Alliance files with the Securities and Exchange Commission from time to time, including the last Form 10-KSB and Form 10-QSB. Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Alliance Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
2. Lung Cancer Alliance Commends NCCN on Screening Guidelines
3. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...che- , , MONTVALE, N.J., Nov. 19 /PRNewswir...aq: MEMY ) today announced that it has achieved .../MEM 3454, its lead alpha-7 nicotinic receptor ago...zophrenia (CIAS). The Company has randomized 212 ...illion payment from its partner Roche. Memory Pha...
(Date:11/18/2008)...arn more, make a donation or send a Christmas Seal...e-USNewswire/ -- Millions will receive Christmas S...can Lung Association. These decorative holiday sta...ting back to 1907 when the Lung Association led ef...Americans alive today have no vivid memories of ho...
(Date:11/18/2008)...USNewswire/ -- Forty-two leading U. S. scientists ...rum to consider cutting-edge innovations that may ...y from outbreaks of dangerous zoonotic diseases, t...hose innovations: , , , , A "Do...etects highly contagious and dangerous zoonotic di...
(Date:11/18/2008)...iagnosed, elderly AML patients , , PRINCETO...ticals today announced that the first patient has ...y of CPX-351 (Cytarabine:Daunorubicin) Liposome In...loid leukemia (AML). , , The first patient ...ical College of Cornell University and New York P...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 1Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 2Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 1Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 2Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 1Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 1Concord Grape Juice Has No Significant Impact on Body Weight 3209 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 3
... of market dynamics offers insights into,what will...to,patients, NEW YORK, May 14, 2007 /PRNewswire-US...pment (TB Alliance), a not-for-profit,product dev...d,development of new TB drugs, today released resu...mics of the global TB drug market,that offers a de...
...pitalization and drug withdrawal, CHICAGO, May 15,...migraine patients and physicians commissioned by t...arris Interactive shows that,20 percent of migrain...ive medications that contain barbiturates or opioi... Drug Administration for the,relief of migraines. ...
Other Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)... Va., Nov. 21 The Gener... following statement today from,GPhA President an...Commission,(FTC) roundtable on "Emerging Health C...e mere fact that the FTC is conducting this roundt...uring that consumers have access to safe and,affo...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2
...umpy old man’, ‘old fogies’ and other such, this i...ersity//. Surprisingly, it’s older people who are ... that people become more positive as they get olde...d to have a "glass empty" view of the world. As ...
...that can keep arteries healthy and prevent heart a...ast one orange// a day could keep cardiac disease ...anones that reduced blood cholesterol levels by 20...on rats, reported the online edition of Daily Mail...
... stress better than those live single, says a stud...r//. Popular perception is that single people have...ws that being in a loving relationship makes it ea...ains of working life, reported online edition of D...
... at Weill Cornell Medical College could prove a po...The compound, called SS31, is able to cross the bl...molecule recently linked to stroke-related tissue ...s, we found that exposing mice to SS31 after an in...
Other Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: